Table 1. Drug target groupings.

Drug targets with iLINCS signatures that are in use or under investigation for the treatment of COVID-19 were grouped together if they met a least two of the three following criteria: Canonical Mechanism of Action, referenced from the database DrugBank (https://www.drugbank.ca/); Anatomic Therapeutic Chemical classification, referenced from https://www.whocc.no/atc ddd index/: structural similarity as determined by intracluster Tanimoto coefficient. F = Febratininb; R = Ruxolinitib; B = Bariticinib

Drug Cluster	Drug	Canonical Mechanism of Action	Anatomical Therapeutic Chemical First Level	Tanimoto Coefficient
1	Chloroquine Hydroxychloroquine	Toll-like receptor antagonists	Antiparasitic Products, Insecticides and Repellants	0.84
2	Lopinavir Ritonavir	Protease inhibitors	Anti-infective for Systemic Use	0.72
3	Fedratinib Ruxolinitib Bariticinib	JAK inhibitors	Antineoplastic and Immunomodulating Agents	F − R: 0.25 F − B: 0.20 B − R: 0.72
4	Azithromycin	Macrolide antibiotic	Anti-Infective for Systemic Use	1
5	Losartan	Angiotensin receptor blocker antagonist	Cardiovascular System	1